Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) [clinicaltrials:NCT02312687]

Bio2RDF uri

Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) [clinicaltrials:NCT02312687]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT02312687

Bio2RDF identifier

NCT02312687

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT02312687

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

UX023-CL203 is a Phase ...... duration of the study.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:other outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:other-outcome]

Incidence, frequency, and severity of adverse events and serious adverse events 72 Weeks [clinicaltrials_resource:043beadb3a6c60ba13a84f22cf0cf9b6]

Incidence, frequency, and severity of adverse events and serious adverse events 72 Weeks [clinicaltrials_resource:0604af60ef0fb7abe3209ceb155d3fca]

Incidence, frequency, and severity of adverse events and serious adverse events 72 Weeks [clinicaltrials_resource:0a1438a70a0681e36d0b6149fde4b19d]

Incidence, frequency, and severity of adverse events and serious adverse events 72 Weeks [clinicaltrials_resource:673aa8bb3d693bfaf2cad3b7d88647ac]

Incidence, frequency, and severity of adverse events and serious adverse events 72 Weeks [clinicaltrials_resource:6ae39cd5715f501efd227e2f4e717c86]

Incidence, frequency, and severity of adverse events and serious adverse events 72 Weeks [clinicaltrials_resource:de8884b8ea050e07982cdab4258a3567]

Incidence, frequency, and severity of adverse events and serious adverse events 72 Weeks [clinicaltrials_resource:f34011eb02277245ecb17d47c8315da1]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Incidence, frequency, and severity of adverse events and serious adverse events 72 Weeks [clinicaltrials_resource:ef95bdffed661e3827df5af015307b7d]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Incidence, frequency, and severity of adverse events and serious adverse events 72 Weeks [clinicaltrials_resource:043fe225b024a845ab88e3359cd16df0]

Incidence, frequency, and severity of adverse events and serious adverse events 72 Weeks [clinicaltrials_resource:0648277d9ffea916a6d800db617146f6]

Incidence, frequency, and severity of adverse events and serious adverse events 72 Weeks [clinicaltrials_resource:36b8fb273322f80435c9f760562b82a6]

Incidence, frequency, and severity of adverse events and serious adverse events 72 Weeks [clinicaltrials_resource:413fa0f9c1233477a459db53e8f78f5b]

Incidence, frequency, and severity of adverse events and serious adverse events 72 Weeks [clinicaltrials_resource:52f4f79cb53352b9878f6181c0d26321]

Incidence, frequency, and severity of adverse events and serious adverse events 72 Weeks [clinicaltrials_resource:63ccc8f023d6effa7d8b166874c1b339]

Incidence, frequency, and severity of adverse events and serious adverse events 72 Weeks [clinicaltrials_resource:7a3b963524d2d9a0a34398d1ba30b83a]

Incidence, frequency, and severity of adverse events and serious adverse events 72 Weeks [clinicaltrials_resource:a41e9645acfeb49c5139fc02429ee2bb]

Incidence, frequency, and severity of adverse events and serious adverse events 72 Weeks [clinicaltrials_resource:c302d9aa65a1c15ccdfaf31562ed662b]

collaborator [clinicaltrials_vocabulary:collaborator]

Ultragenyx Pharmaceutical Inc [clinicaltrials_resource:0ab5bb3e348de673d54ad03434b48b80]

completion date [clinicaltrials_vocabulary:completion-date]

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

X-Linked Hypophosphatemia [clinicaltrials_resource:9d799b3ffdf875b5fbf67703da316fe4]

condition browse [clinicaltrials_vocabulary:condition-browse]

Familial Hypophosphatemic Rickets [clinicaltrials_resource:006826d8a5a33853dc7d808c29d5eba5]

Hypophosphatemia [clinicaltrials_resource:ae437da0b730fc00e23d6b8b44b99f2e]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Familial Hypophosphatemic Rickets [clinicaltrials_resource:006826d8a5a33853dc7d808c29d5eba5]

Hypophosphatemia [clinicaltrials_resource:ae437da0b730fc00e23d6b8b44b99f2e]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT02312687 [clinicaltrials_resource:e43413856bdada803622b1c7d4dc0577]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2014-12-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

KRN23 [clinicaltrials_resource:57c039de7257f4a464329eaf9913ea8f]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

FGF23

http://www.w3.org/2001/XMLSchema#string

KRN23

http://www.w3.org/2001/XMLSchema#string

XLH

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Ultragenyx Pharmaceutical Inc [clinicaltrials_resource:0ab5bb3e348de673d54ad03434b48b80]

location [clinicaltrials_vocabulary:location]

University California San Francisco Hospital [clinicaltrials_resource:8ab86d7d3695a49fddeb8fafc52f5bb5]

nct id [clinicaltrials_vocabulary:nct-id]

NCT02312687

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase 2b, Open-Label, Long-T ...... -Linked Hypophosphatemia (XLH)

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

UX023-CL203

http://www.w3.org/2001/XMLSchema#string

overall status [clinicaltrials_vocabulary:overall-status]

Enrolling by invitation [clinicaltrials_resource:de22780fc0a98a3784adc8f05610d3c1]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:965595316c5ae1a4521a298d475eb908]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

Ultragenyx Pharmaceutical Inc [clinicaltrials_resource:0ab5bb3e348de673d54ad03434b48b80]

start date [clinicaltrials_vocabulary:start-date]

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT02312687 study design [clinicaltrials_resource:c6bde5b307340ba7eeb36545c8f1ec2b]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT02312687

verification date [clinicaltrials_vocabulary:verification-date]

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT02312687

http://www.w3.org/2001/XMLSchema#string

title

Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Long-Term Extension Study of K ...... ) [clinicaltrials:NCT02312687]

@en